Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain.

ABSTRACT: We have been exploring biomarkers that could help physicians select the appropriate opioid for individualized treatment of cancer pain. Recently, we identified a single nucleotide polymorphism (SNP) of CCL11 (rs17809012) as one such biomarker that was significantly associated with the analgesic effect of morphine. The current study measured the plasma concentrations of chemokines/cytokines in pre-treatment plasma samples of a total of 138 patients who were randomized to receive morphine (n=70) or oxycodone (n=68). Based on the results, one cytokine, IL-16, was identified whose plasma concentrations showed a clear bias between patients with cancer pain who responded well and responded poorly to oxycodone. A genotypic analysis also identified a SNP of the IL-16 gene (rs4778889)

SUBMITTER: Fujita Y 

PROVIDER: S-EPMC11667419 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature